Simulations Plus acquired by Altaris for $18.50/share
Simulations Plus, Inc., a developer of model-informed and AI-accelerated drug development software, has been acquired by Altaris, LLC, an investment firm focused on the healthcare industry. The transaction, originally announced on June 16, 2026, values the company at $18.50 per share in cash. Simulations Plus will now operate as a privately held company and will be combined with CCG, another Altaris portfolio company.
Story updates
01:16:04 PM UTC
SquawkNews
Altaris completed its acquisition of Simulations Plus, paying $18.50 per share in cash. Simulations Plus became privately held, ending trading of its common stock on the Nasdaq Global Select Market. The deal was first disclosed on June 16, 2026. * Closing pairs Simulations Plus with Altaris-owned Chemical Computing Group to build a broader drug discovery and development software platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via (Ref. ID: 202610060915BIZWIRE_USPR_____20261006_BW258966) on October 06, 2026, and is solely responsible for the information contained therein. (C)